Redefining Drug Repurposing
Fifty1 AI Labs is redefining drug discovery with an intelligent platform built for speed, safety, and scale.
We harness biomedical data and applied machine learning to uncover new uses for existing compounds — reducing risk, accelerating development, and unlocking untapped value in molecules that already work. By focusing on proven therapies with established safety profiles, we shorten the path from insight to impact.
Fifty1 AI completed a pioneering Phase III adaptive trial for Long COVID—unlocking a new therapy using safe, repurposed medicines.
What We’re Doing:
Long COVID affects millions, yet treatments remain limited. Fifty1 AI combined adaptive trial design with AI analytics to uncover an effective, low-cost therapy—demonstrating the speed, flexibility, and power of our discovery platform.
Why It Matters:
- First-of-its-kind trial in Long COVID, run end-to-end by Fifty1 AI
- Real-time, adaptive design: Treatments added or removed based on live data
- Validated result: A new therapy using safe, widely available medicines
- Scalable model for rapidly evaluating therapies in chronic and emerging diseases
What’s Next:
Results are under peer review at a leading medical journal—marking a milestone for AI-driven, cost-efficient therapeutic discovery.
Let’s Talk:
Investors and partners seeking scalable, capital-smart drug development—connect with us.
In partnership with top U.S. universities, Fifty1 AI is developing next-gen performance supplements—customized by sport, role, and biology.
What We’re Doing:
We’re collaborating with Division I athletic programs to create data-backed, sport-specific supplement strategies for performance, recovery, and endurance. Using biometrics and AI, we optimize formulas for real-world impact—field-tested by athletes, informed by coaches and nutritionists.
Why It Matters:
- Trusted by elite collegiate teams
- AI-personalized supplements by sport, position, and physiology
- Validated in live trials across campuses
- Brand reach via athlete ambassadors and trusted sports networks
Market Opportunity:
A $49.6B market (2024), growing at 16.2% CAGR. Fifty1 AI is building the most credible, data-driven supplement line in performance wellness.
Get in the Game:
Join us in shaping the future of athletic nutrition. We welcome investor and strategic partner conversations.
Fifty1 AI is advancing drug repurposing through faster, smarter delivery—bypassing the gut to boost absorption and unlock IP opportunities.
What We’re Doing:
We’re combining adaptive trials and AI to evaluate familiar drugs in new formats—patches and under-the-tongue delivery—for faster action, improved compliance, and fresh commercial potential. Early focus areas include testosterone, HRT, SSRIs, and Botox.
Why It Matters:
- AI-guided formulation: Matches drugs with optimal delivery method
- Adaptive trials streamline development—drop failures early, fast-track success
- Novel formats for known drugs
= lower risk, higher value - Tapping high-growth markets in mental health, wellness, and chronic care
Market Potential:
The transmucosal delivery market will reach ~$86.6B by 2034. Our approach offers a smarter, faster route to market for repurposed therapeutics.
Partner with Us:
If you believe innovation lies in how we deliver medicine—not just what—let’s connect.
Inside the Lab
Our AI-driven platform integrates clinical data, chemical intelligence, and regulatory insight to identify high-value candidates primed for fast-track development — delivering efficient, evidence-based therapies at scale.
Our Focus
We target functional and wellness-related conditions where off-patent drugs hold untapped potential.
As chronic illness rises globally, our AI platform integrates clinical data, chemistry, and regulatory insights to identify safe, repurposable compounds—delivering faster, smarter therapies that meet the demand for holistic, cost-effective solutions in an evolving healthcare landscape.
Global Scope
The global health and wellness market is projected to grow from USD 6.87 trillion in 2025 to approximately USD 11 trillion by 2034, expanding at a CAGR of 5.40%.[*]
Harnessing advancements in AI and data-driven approaches Fifty1 AI Labs are well-positioned to capitalize on these expanding markets by delivering innovative, cost-effective therapies that address chronic diseases and enhance overall well-being.
Backed by Fifty1 Labs
Fifty1 Labs, our parent company, is committed to advancing intelligent health innovation. With a $1 million R&D investment already fueling our AI drug repurposing platform, they provide the strategic foundation and long-term vision behind everything we’re building at Fifty1 AI Labs.
Reshape Healthcare through AI-Driven Drug Repurposing
Uplisting to OTCQBand NASDAQ
Boosting investor visibility and liquidity through stock market listings.
DigitalEngagement
Connecting with stakeholders through interactive digital platforms.
StrategicAcquisitions
Enhancing R&D and market presence via biotech acquisitions.
R&DLeadership
Advancing AI-driven drug repurposing with 1MM R&D investment.